Expansion of Genedata's Collaboration with Serono into High Content Screening
Genedata announced the expansion of its screening analysis collaboration with Serono. Scientists at Serono now use Genedata's computational solution to combine results from high content screening assays with chemical and pharmacological information as part of the process to identify promising candidates for drug development.
High content data from cellular assay technologies used at Serono enable sophisticated biological profiling. These screening technologies provide insights into the biological effects of potential drug candidates, including possible toxic side effects. To exploit these technologies, screening results need to be shared among people with different expertise, including chemists and toxicologists.
During the course of the collaboration, Genedata extended its Screener® result management and analysis solution, enabling Seronos researchers to analyze and annotate their screening results more efficiently. The collaboration quickly reached the point where the software was a precise fit with Seronos needs, according to the company.
Other news from the department business & finance
These products might interest you

Limsophy by AAC Infotray
Optimise your laboratory processes with Limsophy LIMS
Seamless integration and process optimisation in laboratory data management

ERP-Software GUS-OS Suite by GUS
Holistic ERP solution for companies in the process industry
Integrate all departments for seamless collaboration

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Santhera Presents New Data on MC-4R Antagonist Program for Treatment of Cancer Cachexia

IKA G-L | Midi centrifuges | IKA Werke
